ÂÜÀòÂÒÂ×

Michael Wyzga has served as a director since October 2013 and as their Chairman since March 2016. Mr. Wyzga is currently the President of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting. Prior to that, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. (Nasdaq: RDUS), a biopharmaceutical company, from

December 2011 until November 2013.

Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a biopharmaceutical company, which was acquired by Sanofi in 2011. Mr. Wyzga joined Genzyme in February 1998 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as Chief Financial Officer from July 1999 until November 2011.

Since February 2014, Mr. Wyzga has served as a member of the board of directors of Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company, where he is also a member of the compensation committee and chair of the audit committee. Since February 2013, Mr. Wyzga has also served as a member of the board of directors and chair of the audit committee of OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a biopharmaceutical company.

Since February 2015, Mr. Wyzga has also served as a member of the board of directors of Exact Sciences Corporation (Nasdaq: EXAS), a medical technology company, where he is also a member of the audit and compensation committees.

Mr. Wyzga also previously served as a member of the board of directors of Idenix Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Merck in August 2014, where he also served as the chair of the audit committee and a member of the compensation committee, Altus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company that ceased operations in November 2009, and as a member of the supervisory board of Prosensa Holding B.V., or Prosensa, a publicly traded biopharmaceutical company, from June 2014 until the Prosensa acquisition by BioMarin Falcon B.V. in December 2014. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.